Abstract 2097P
Background
OM is one of the main adverse events during chemotherapy, affecting around 40% of pts; it is characterized by an inflammation and ulceration of the oral mucous membranes that can lead to oral pain, impaired nutritional intake, local or systemic infections and lower quality of life. Only few strategies are available for its prevention and management. FP-based tp can cause OM due to their cytotoxic effect on mucosal cells inducing DNA double strand brakes and ROS production, empowered by TNF-alfa release. In our retrospective monocentric study we evaluated clinical and hematological RFs which could help us to identify early those patients who might benefit the most from a preventive strategy.
Methods
We evaluated incidence, management and possible RFs for OM (such as diabetes, smoke, BMI and blood inflammation markers) on 174 pts treated with a FP-based tp during a typical month in our DH. Statistical analysis has been conducted using Chi-square test and Fisher’s exact test. Pts have been informed about risk of developing OM and we subsequently managed the symptom on the basis of its severity according to CTCAE.
Results
48 pts developed OM. We found a higher OM incidence in smoker pts (60.5% vs 21.4% in non smoker, p<0.0001) and in overweight pts (39.7% vs 24.1% in pts with normal weight, p=0.0381). We also demonstrated a correlation between a higher OM severity and diabetes diagnosis (71% vs 29.8% in non diabetic pts, p=0.0330). No statistically significant correlation emerged between OM incidence/severity and any of the blood values tested (blood cells values, NLR, PLR, creatinine). 20 pts had ≥G2 OM and received local and/or systemic therapies, while 3 pts needed a treatment suspension. Median time to resolution was 28 days. 6 pts still had OM of various severity grade at the time of our analysis.
Conclusions
Smoke and overweight could be RFs for OM incidence of any grade during a FP-based treatment, while a diabetes diagnosis seemed to be related with a higher severity of OM, but not with its incidence. In view of the above, it might be useful to recommend accurate oral hygiene and a preventive strategy in accordance with MASCC guidelines in these subgroups of pts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06